Nationwide utilization of antidepressants and anxiolytics during pandemic restrictions: results from the Trends in Drug Utilization During COVID-19 Pandemic in Turkey (PANDUTI-TR) study

The prevalence of mental health disorders rose when the impact of the COVID-19 pandemic was most pronounced, potentially altering the consumption of antidepressants and anxiolytics. We aimed to evaluate changes in antidepressant and anxiolytic utilization throughout the COVID-19 pandemic era. Nation...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Family practice Ročník 42; číslo 5
Hlavní autoři: Vizdiklar, Caner, Aydin, Volkan, Yilmaz, Hakan, Akici, Ahmet
Médium: Journal Article
Jazyk:angličtina
Vydáno: England 14.08.2025
Témata:
Anti-Anxiety Agents - therapeutic use
Antidepressive Agents - therapeutic use
COVID-19 - epidemiology
Depression - drug therapy
Drug Utilization - statistics & numerical data
Drug Utilization - trends
Humans
Male
Pandemics
Practice Patterns, Physicians' - statistics & numerical data
Practice Patterns, Physicians' - trends
SARS-CoV-2
Turkey - epidemiology
Turkey
COVID-19 pandemic
anxiety disorders
drug utilization
mood disorders
ISSN:1460-2229, 1460-2229
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:The prevalence of mental health disorders rose when the impact of the COVID-19 pandemic was most pronounced, potentially altering the consumption of antidepressants and anxiolytics. We aimed to evaluate changes in antidepressant and anxiolytic utilization throughout the COVID-19 pandemic era. Nationwide drug sales and prescribing data through 01.03.2018-31.12.2022 were sourced from IQVIA Turkey. We assessed mean monthly consumption and expenditure trends of antidepressants and anxiolytics, along with quarterly prescribing levels, across three periods: "before restrictions" (BfR, 01.03.2018-31.03.2020), "during restrictions" (DuR, 01.04.2020-31.03.2022), and "after restrictions" (AfR, 01.04.2022-31.12.2022), using "defined daily dose per 1000 inhabitants per day" (DID) measure. Antidepressant consumption escalated from 47.9 ± 4.3 DID in BfR to 56.2 ± 8.9 DID in DuR (P < .001), reaching 60.5 ± 8.9 DID in AfR (P < .001 vs. BfR). Anxiolytic use increased from 2.0 ± 0.3 DID in BfR to 2.5 ± 0.3 DID in DuR (P < .001), and to 2.7 ± 0.3 DID in AfR (P < .001 vs. BfR). Expenditure also rose in DuR and AfR for both drug groups (P < .01). Prescribing trends for antidepressants decreased in DuR (P < .001) and showed an insignificant rebound in AfR (P > .05 vs. BfR and DuR), while anxiolytic prescribing surged in DuR (P = .001 vs. BfR) and subsequently reverted in AfR (P > .05 vs. BfR and DuR). These patterns were consistent across both new and ongoing users. This study showed a sustained increase in the use of antidepressants and anxiolytics following the onset of pandemic despite fluctuations in prescribing, implying a heightened need for pharmacotherapy and greater burden of depressive and anxiety disorders, especially for the latter.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1460-2229
1460-2229
DOI:10.1093/fampra/cmaf072